Prevention of VTE: elective hip or knee replacement surgery.
Prevention of stroke and systemic embolism: nonvalvular atrial fibrillation.
Treatment of VTE.
Adult & Geriatric: Prophylaxis of DVT: Oral 2.5 mg twice a day, 12-24 hours for 35 days for hip surgery and 12 days for knee surgery.
Prevent stroke and systemic embolism: Oral 5 mg twice a day, reduce dose to 2.5 mg twice a day if patient has 2 of 3: Age ≥ 80 years, body weight ≤ 60 kg, or serum creatinine ≥ 1.5 mg/dL.
DVT/PE: Oral 10 mg twice a day for 7 days followed by 5 mg twice a day.
Reduce risk of DVT/PE: Oral 2.5 mg twice a day after at least 6 months of treatment.
Pediatric and adolescent: In children below age 18 have not been established.
Method of Administration: Oral. Administer without regard to meals.
Hypersensitivity to apixaban or any component; Active pathological bleeding.
Increase risk of bleeding.
Premature discontinuation increases the risk of thrombotic events.
Not recommended as an alternative to unfractionated heparin for initial treatment of acute PE.
Patients with prosthetic heart valves or significant rheumatic heart disease use is not recommended.
Increased gamma-glutamyl transferase, increased serum transaminase, gingival hemorrhage, nausea, hematuria, hypermenorrhea, anemia, bruise, hematoma, hemorrhage, postprocedural hemorrhage, rectal hemorrhage, epistaxis, hemoptysis.
Concurrent with anticoagulants, antiplatelets, SNRIs, SSRIs, ticagrelor, nefazodone and grapefruit juice may increase risk of bleeding.
Concurrent with combined P-glycoprotein/strong CYP3A4 may effected exposure of apixaban.
Concurrent with fluconazole/itraconazole increased apixaban exposure and risk for toxicity.
B01AF02 - apixaban ; Belongs to the class of direct factor Xa inhibitors. Used in the treatment of thrombosis.
Exaban tab 2.5 mg
1 × 10's;10 × 10's;3 × 10's;6 × 10's
Exaban tab 5 mg
1 × 10's;10 × 10's;3 × 10's;6 × 10's
Sign Out
